Emerging data suggest this peptide, a dual activator targeting both the gut-brain axis and GIP , appears to represent a promising advancement for weight management . Early clinical trials have indicated impressive reductions in abdominal fat , possibly outperforming current weight-loss therapies . Nevertheless , additional evaluation is needed to t